Nutropin is a human growth hormone (hGH) which has been produced through recombinant DNA technology. It has a molecular weight of 22,125 daltons and an amino acid sequence which is identical to that of the hormone derived from the pituitary gland.
It is estimated that the product may contain up to 15% deamidated GH at expiration; however, this form of GH has been studied extensively and has been found to be safe and effective.
Nutropin therapy is used to replace endogenous GH in adults who have a deficiency due to pituitary disease, hypothalamic disease, surgery, radiation therapy, or trauma.
Additionally, it can be used to replace GH deficiency in children who have already closed their epiphyses. In these cases, it is important to evaluate the patient again in order to ensure that the therapy is still appropriate.
Nutropin, a therapeutic equivalent to naturally-occurring human growth hormone (hGH), has been extensively tested both in vitro and in vivo, as well as preclinically and clinically. When given to pediatric patients with inadequate endogenous GH production, chronic renal insufficiency, and Turner syndrome, Nutropin has been shown to increase growth rate and insulin-like growth factor-I (IGF-I) levels similar to those seen with pituitary-derived hGH.
Nutropin is a white, sterile powder that is meant to be injected subcutaneously after it has been reconstituted with Bacteriostatic Water for Injection USP (containing benzyl alcohol).
After reconstitution, the product is close to isotonic, with a concentration of 5 mg per milliliter of growth hormone and a pH of approximately 7.4. Each 10 mg Nutropin vial contains 10 mg of somatropin (roughly 30 IU), 90 mg of mannitol, 0.8 mg of sodium phosphate monobasic, 2.6 mg of sodium phosphate dibasic, and 3.4 mg of glycine.
The proper dosage and frequency of Nutropin injections should be determined on an individual basis. Generally, the effectiveness of growth hormone therapy in pediatric patients tends to diminish over time.
If a child’s growth rate is not increasing, particularly during the first year of treatment, it is important to make sure that the patient is following the prescribed regimen and to rule out other potential causes of growth failure, such as hypothyroidism, malnutrition, and advanced bone age.
Nutropin for anti-aging
Nutropin therapy is prescribed by doctors for adults who have growth hormone deficiency that was caused by pituitary disease, diseases of the hypothalamus, surgery, radiation therapy, or trauma; as well as for those who experienced growth hormone deficiency in childhood.
Individuals who had growth hormone deficiency during childhood and whose bones have stopped growing should have a reevaluation to determine if they still require growth hormone therapy.